About Tumor necrosis factor ligand superfamily member 6
Tumor necrosis factor ligand superfamily member 6 (FASLG) is a protein
from Homo sapiens identified by UniProt accession
P48023, 281 residues long.
MolForge cross-references it against 0 known binders and
1,367 disease associations.
Target properties
| Protein name | Tumor necrosis factor ligand superfamily member 6 |
|---|
| UniProt accession | P48023 |
|---|
| Gene | FASLG |
|---|
| Organism | Homo sapiens |
|---|
| Length | 281 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (1367)
Diseases linked to this target (Open Targets).
- autoimmune lymphoproliferative syndrome · score 0.66
- celiac disease · score 0.39
- allergic disease · score 0.38
- neutrophil count · score 0.37
- eosinophil count · score 0.37
- type 1 diabetes mellitus · score 0.36
- Eczematoid dermatitis · score 0.35
- immunodeficiency 98 with autoinflammation, X-linked · score 0.35
- myeloid white cell count · score 0.34
- COVID-19 · score 0.30
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P48023-F1 | alphafold | PREDICTED | 80.20 | — |
Amino-acid sequence (281 residues)
MQQPFNYPYP QIYWVDSSAS SPWAPPGTVL PCPTSVPRRP GQRRPPPPPP PPPLPPPPPP PPLPPLPLPP LKKRGNHSTG LCLLVMFFMV LVALVGLGLG MFQLFHLQKE LAELRESTSQ MHTASSLEKQ IGHPSPPPEK KELRKVAHLT GKSNSRSMPL EWEDTYGIVL LSGVKYKKGG LVINETGLYF VYSKVYFRGQ SCNNLPLSHK VYMRNSKYPQ DLVMMEGKMM SYCTTGQMWA RSSYLGAVFN LTSADHLYVN VSELSLVNFE ESQTFFGLYK L
Explore Tumor necrosis factor ligand superfamily member 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets